)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Genetic Analysis
Genetic Analysis (GEAN) investor relations material
Genetic Analysis Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary28 Aug, 2026
Executive summary
Achieved recurring revenue growth in core reagent kit products, with global expansion and scientific validation supporting platform adoption.
Launched Alnsight, an AI-assisted interpretation platform, and advanced the GA-map® IBD Precision Dx project toward a 2026 launch.
Secured a new US patent and expanded laboratory installations to Australia, now covering four continents.
Financial highlights
Q2 2026 sales revenue was NOK 5.3 million, down 10.2% year-over-year (4% decrease at constant currency).
Gross margin reached 91.2% in Q2 2026, positively impacted by a one-time accrual for US customs duty refunds; adjusted gross margin was 72.5%.
EBITDA for Q2 2026 was NOK -1.0 million, compared to NOK 0.5 million in Q2 2025.
Net loss for Q2 2026 was NOK -2.4 million, compared to NOK -1.0 million in Q2 2025.
Cash and cash equivalents at June 30, 2026, were NOK 14.5 million, down from NOK 24.0 million at year-end 2025.
Outlook and guidance
Expects continued revenue growth driven by increased adoption of GA-map® solutions and expansion in Europe, US, and China.
Anticipates new customer interest with the launch of GA-map® IBD Precision Dx in H2 2026.
Growth to be supported by scaling reagent kit sales, demand for standardized microbiome testing, and new product rollouts.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Genetic Analysis
- Q1 2026 revenue rose 60% year-over-year, with strong kit sales and new product launches.GEAN
Q1 2026 - Record sales and US expansion drive growth, with improved net loss and strong cash position.GEANQ4 2025
- Q3 2025 sales rose 2.9% year-over-year, with new product launches and US expansion driving growth.GEANQ3 2025
- Q2 2025 delivered strong sales growth, positive EBITDA, and strategic expansion in key markets.GEANQ2 2025
- Core kit sales up 32% YTD; cost cuts and new products drive improved margins and outlook.GEANQ3 2024
- Reagent kit sales soared 135% in Q2 2024, fueling growth and supporting US expansion.GEANQ2 2024
- Sales down, margins up, China entry and capital raise position GA for future growth.GEANQ1 2025
- Record sales, first positive EBITDA, and a key pharma partnership drive future growth.GEANQ4 2024
Next Genetic Analysis earnings date
Q3 202626 Nov, 2026
Genetic Analysis
Next Genetic Analysis earnings date
Q3 202626 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Genetic Analysis develops and markets diagnostic tests based on microbiome profiling technologies. Its solutions are used in healthcare and research to analyze gut microbiota for disease risk and treatment optimization. The company is headquartered in Oslo, Norway, and its shares are listed on the Spotlight Stock Market.